Bone is a frequent site of metastases and typically indicates a short-term prognosis in cancer
patients. Once cancer has spread to the bones it can rarely be cured, but often it can still be …

The first full publications on the biological effects of the diphosphonates, later renamed
bisphosphonates, appeared in 1969, so it is timely after 40 years to review the history of their …

Bisphosphonates (BP) are a class of calcium-binding drug used to prevent bone resorption
in skeletal disorders such as osteoporosis and metastatic bone disease. They act by …

Background Bisphosphonates reduce the risk of skeletal events in patients with malignant
bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and …

The ability of bisphosphonates ((HO) 2 P (O) CR 1 R 2 P (O)(OH) 2) to inhibit bone
resorption has been known since the 1960s, but it is only recently that a detailed molecular …

Bones provide essential functions and are sites of unique biochemistry and specialized
cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has …

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and
survival. Osteocytes have emerged as key players in the development of myeloma-related …

γδ T cells contribute to the front line of lymphoid antitumor surveillance and bridge the gap
between innate and adaptive immunity. They can be readily expanded to high numbers in …

Annexin A1 (ANXA1) is a Ca2+-regulated phospholipid-binding protein involved in various
cell processes. ANXA1 was initially widely studied in inflammation resolution, but its …

Bone-targeted treatments with bisphosphonates and denosumab, which reduce bone
resorption, are known to reduce the risk of skeletal complications and prevent treatment …